(NASDAQ:FA), ATLANTA, Nov. 04, 2025 (GLOBE NEWSWIRE) — First Advantage Corporation (NASDAQ: FA), a leading provider of global software and data in the HR technology industry, today announced the Company's management team will participate in the following upcoming investor conferences: J.P. Morgan Ultimate Services Investor ConferenceDate: Tuesday, November 18, 2025Location: New York CityFormat: Webcast at […]
(NasdaqGM:PRE), CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever
(NASDAQ:PCTY), Q1 2026 Recurring & Other Revenue of $378.9 million, up 14% year-over-year Q1 2026 Total Revenue of $408.2 million, up 12% year-over-year Repurchased $200 million or 1.2 million shares in Q1 Fiscal Year 2026; $500 million or 3.0 million shares repurchased since May 2024 Announcing updated long-term financial targets, including increased Adjusted EBITDA and
OnKure Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire November 04, 2025 BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) — OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one
Inspirato Reports Q3 Financial and Operating Results Operational efficiencies drive $15.0 million of year-to-date improved cash flow from operating activities and $13.2 million increase in adjusted EBITDA, strengthening the foundation for efficient growth ahead GlobeNewswire November 04, 2025 DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the “Company”) (Nasdaq: ISPO), the premier
(NASDAQ:SLDB), CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 26,550 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of
(NASDAQ:SPRO), CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13,
(NASDAQ:RVMD), REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in two upcoming investor conferences. Details of the company's participation
Solana Company Files Application to Cease to Be a Reporting Issuer in Canada GlobeNewswire November 04, 2025 NEWTOWN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (“Solana” or the “Company“) today announced that it has applied to the British Columbia Securities Commission, as principal regulator, and the Ontario Securities Commission, for an
(NASDAQ:LGVN),(NASDAQ:LGVNR), On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled. ELPIS II may serve as foundation for a Biologics License Application